What I'm Working On

My translational research has focused on oncogenesis, drug resistance, molecular immunology and prognostic and predictive biomarkers. My laboratory discovered the anti-apoptotic protein BAG-1 as a prognostic factor in solid tumors; and developed novel BAG-1-targeted therapy. I currently have three active ACS/DOD grants for which I serve as co-investigator or collaborator.

 

Biography

Shou-Ching Tang, MD, PhD, FACP, FRCPC, is a world-renowned clinician scientist and cancer center administrator with a passion for cancer clinical and translational research and breast cancer prevention, diagnosis, and treatment. He is certified in medical oncology by the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada. He currently serves as associate dean of translational research and tenured professor at the LSU Health New Orleans School of Medicine, associate director for clinical research at the LSU LCMC Health Cancer Center, and director of the phase I clinical trials program.

As associate director for clinical research, Dr. Tang will be responsible for organizing research programs in clinical research that foster collaboration, innovation, and impact, and engaging members and facilitating careers in clinical cancer research. In addition, Dr. Tang will be working with junior clinical faculty as part of a mentoring program.   

As the associate dean for translational research, Dr. Tang provides leadership and strategic direction on the clinical and translational research efforts across the LSU Health New Orleans  School of Medicine.

Prior to joining the LSU LCMC Health Cancer Center, Dr. Tang was with the University of Mississippi Medical Center, where he served as the associate director for clinical and translational research at the Cancer and Research Institute, director of the phase I clinical trials and interdisciplinary experimental therapeutic program and chair of clinical leadership council for cancer service line. He has also held leadership positions at academic institutions and NCI-Designated Cancer Centers, including the Georgia Cancer Center; endowed chair in medical oncology at the Virginia Piper Cancer Institute; director of clinical research with the Allina Health System; professor and chief of hematology/oncology at the Denver Health Medical Center (University of Colorado); professor and director of breast program at the Mayo Clinic (Scottsdale, AZ); and associate cancer center director for clinical research at the University of Miami Sylvester Comprehensive Cancer Center. He currently serves on the Department of Defense (DOD) Clinical and Experimental Therapeutics 10 (CET-10) Peer Review Panel, SWOG Breast Cancer and Immunotherapy Committees. He is a senior member of the American Association for Clinical Oncology (ASCO) and American Association for Cancer Research (AACR) and Fellow of American College of Physician (ACP) and Royal College of Physicians and Surgeons of Canada (FRCPC). 

Dr. Tang earned his doctorate with honors from West China University of Medical Sciences and a PhD degree in molecular biology from the University of Alberta in Edmonton, Alberta, Canada. He completed his medical oncology fellowship at the Princess Margaret Hospital (Toronto, Canada). After graduation, Dr. Tang served as the director of medical oncology and cancer research at the Newfoundland Cancer Treatment and Research Foundation and was a member of the specialty committee in medical oncology for the Royal College of Physicians and Surgeons of Canada, and the Canadian Association of Medical Oncologists (CAMO). Dr. Tang founded the Asia International Breast Cancer Summit (AIBCS) and has chaired its annual meetings in Asia since its conception in 2007. He was the Founding President of the Atlantic Canada Oncology Group (ACOG) and the US Chinese Anticancer Association (USCACA). Dr. Tang serves on the editorial boards of six peer-reviewed international journals.

Dr. Tang is a Frances Zuppardo Endowed Professor in Cancer Research.